Urethral Stricture

0
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Verona Pharma
Verona PharmaUK - London
1 program
NANOfat graftingN/A1 trial
Active Trials
NCT05464290Unknown25Est. Jan 2023
City Therapeutics
City TherapeuticsMA - Cambridge
1 program
Uroflowmetry with URI CalculationN/A1 trial
Active Trials
NCT07403786Not Yet RecruitingEst. Jul 2026

Trial Timeline

Clinical trial activity over time

2022
2023
2024
2025
2026
City TherapeuticsUroflowmetry with URI Calculation
Verona PharmaNANOfat grafting

Clinical Trials (2)

Total enrollment: 25 patients across 2 trials

NCT07403786City TherapeuticsUroflowmetry with URI Calculation

Urethral Resistive Index (URI): A New Parameter for Diagnosing Urethral Obstruction

Start: Feb 2026Est. completion: Jul 2026
N/ANot Yet Recruiting
NCT05464290Verona PharmaNANOfat grafting

The Nanofat Regenerative Surgery for Management of Genital Lichen Sclerosus in Male and Female Patients

Start: Jul 2022Est. completion: Jan 202325 patients
N/AUnknown

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space